READY ON DAY 1

Building the world's first comprehensive portfolio of antiviral drugs.

READDI

Rapidly Emerging Antiviral Drug Development Initiative

1,900,000 lives lost worldwide before vaccines were available

75 million people pushed into extreme poverty

255 million global jobs lost in 2020

3.5 percent decrease in global GDP

14 trillion dollars in US economic damage

Imagine if we had been ready

7,054,000 confirmed deaths

1.6 billion students impacted in 190 countries

26,970,000 estimated deaths, based on excess mortality

65 million long COVID cases worldwide

27 percent of global population remains unvaccinated

Pandemics are not rare events

The number of zoonotic spillover events and reported deaths **increased at an exponential rate** from 1963 to 2019.[1]

Annually, there are approximately[2]:

- 100 significant outbreaks (triggering WHO Disease Outbreak News reports)
- 5 new emerging infectious diseases

~25% probability of a pandemic ≥ COVID-19 during 10-year period:

- Metabiota[3] **22%-28%**
- Airfinity[4] **27.5%**

Source:
1. BMJ Global Health, Nov 2023 2. WHO 3. Rebranded Gingko Bioworks 2022 4. London-based disease forecasting company.

Outbreaks in the news since June 2024

"**Dengue** fever is surging worldwide. A hotter planet will make it worse."

The Washington Post, June 30, 2024

"**Mpox** declared a public health emergency."

The Lancet, Aug 24, 2024

"'No turning back': **Unprecedented dengue outbreak in Los Angeles** signals infection tipping point."

The Telegraph, Sep 24, 2024

"**Bird flu** could become a human pandemic. How are countries preparing?"

Nature, July 18, 2024

"A Massachusetts town closes its parks to stop a **mosquito-borne disease** from spreading."

NPR, Aug 26, 2024, re: EE Encephalitis

"**Deadly Marburg virus**: scientists race to test vaccines in outbreak."

Nature, Oct 1, 2024

Viruses have an Achilles' heel

- Viruses cluster into families
- Viruses within each family share common features that can be targeted by antiviral drugs

No one knows which specific viruses come next, but we do know the *families* from which they will likely emerge



broad-spectrum:
effective against multiple viruses in a given family

small molecule drugs:
organic compounds with low molecular weight (think aspirin, not biologics)

GOAL: 2 drugs per high-risk family

- Work against an entire virus family
  - Protect against future threats
  - No need for genetic sequence
- Can be shipped immediately to the point of outbreak
  - Reduce disease, hospitalization and death
  - Slow viral spread

16 drugs total

“Why isn’t anyone else doing this?”

Discovery gap

Academics focus on drug discovery, not drug development.

Pharma model

Businesses develop drugs to target specific indications for existing markets.

Disease X problem

There is no business model to fight diseases that don’t yet exist.

CHALLENGE: Incentivize antiviral R&D to prepare for Disease X

READDI is the solution

A mission-driven biotechnology company acting in the public interest, READDI accelerates broad-spectrum small molecule antiviral discovery and development.

Committed to equitable global access

Addressing market failure to disrupt the panic-neglect cycle of pandemic response

We are aggregating a portfolio of broad-spectrum drugs — from a coalition of innovators at different stages of development — to target all high-risk virus families.



READDI's Global Network: 63 collaborators and growing

Leadership

Founded by world-renowned virologists



Ralph S. Baric
Co-founder and Scientific Adviser



Mark Heise
Co-founder and Scientific Adviser

Nathaniel Moorman
Co-founder and Scientific Adviser

James Rosen
CEO and Director

Fletcher Fairey
Executive VP, Business

Logan Ward
Director of Communications

Select Board Members

John Bamforth
30 years at Eli Lilly

Richard Burr
Former U.S. Senator

Laurent Fraisse
R&D Dir, Drugs for Neglected Diseases Init

Lydia Ogden
Global Public Health R&D Policy and External Engagement Leader, J&J

Barbara Stephenson
UNC Chief Global Officer and former U.S. Ambassador

CORE CAPABILITIES

Management

- Drug discovery and development expertise
- Strategic global network of subject matter experts
- Experience managing multi-site consortiums
- Proven record of managing complex federal grants and contracts
- Diligent program oversight and quality control

Technical

- AI-enhanced drug discovery
- Medicinal chemistry experience with thousands of drug compounds
- Proprietary cell lines, in-vitro/in-vivo systems
- Clinical trial design and operation — animal and human
- Regulatory expertise

READDI is a global leader in antiviral therapeutics R&D

- Core implementation partner in the 100 Days Mission, the global pandemic preparedness effort launched by the G7
- Lead contributor to *100 Days Mission Therapeutics Roadmap*
- Co-leading Therapeutics Development Coalition alongside the WHO, Unitaid, DNDi and others



"The highest priority is to gather resources to support READDI's work. Drugs are the gating item."

— **Jeremy Farrar, WHO Chief Scientist**

Preparing for the next threat

READDI
Rapidly Emerging Antiviral Drug Development Initiative

High-risk virus families

- Encompass all viruses that cause WHO priority diseases
- Likely origin of future Disease X
- No antivirals or vaccines exist to stop Disease X



Arenavirus



Bunyavirus



Coronavirus

Filovirus



Flavivirus



Orthomyxovirus



Paramyxovirus



Togavirus

READDI Prospective Pipeline

- 30 active programs and growing










World-class drug development and innovative financing to prepare humanity for Disease X.

Funders

THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

BATTELLE

SALL FAMILY
FOUNDATION

RTI
INTERNATIONAL

Every antiviral the world will need.



READDI

Rapidly Emerging Antiviral Drug Development Initiative